Document Detail

Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass.
MedLine Citation:
PMID:  8231204     Owner:  NLM     Status:  MEDLINE    
The clotting and fibrinolytic systems are activated by tissue factor and by tissue-type plasminogen activator in the pericardial cavity, where the thrombogenicity is greater than that of the surface of modern extracorporeal circuits. This local activation may have consequences for the systemic activation processes during cardiopulmonary bypass. To test this hypothesis, we investigated blood activation by interrupting the blood suction from the pericardial cavity during cardiopulmonary bypass in clinical coronary artery bypass operations. In blood collected in the pericardial cavity, thrombin-antithrombin III complex (p < 0.01), tissue-type plasminogen activator antigen (p < 0.05), fibrinogen degradation products (p < 0.01), and fibrin degradation products (p < 0.01) were significantly higher than in the systemic blood. Plasma heparin was significantly consumed in the pericardial cavity (p < 0.01). Once the pericardial blood was returned to the systemic circulation after resumed suction during cardiopulmonary bypass, thrombin-antithrombin III complex (p < 0.05), fibrinogen degradation products (p < 0.05), and fibrin degradation product (p < 0.05) concentrations increased significantly in the systemic blood. The effects of pericardial tissue on activation of clotting and fibrinolysis were also studied in vitro. When human plasma was incubated for 5 minutes with rabbit pericardium at reduced heparin concentrations, we found significant generation of thrombin (p < 0.05) and plasmin (p < 0.05). If the thrombin inhibitor hirudin was added, plasmin generation was also inhibited (p < 0.05). The results of the clinical and experimental study are in agreement with our hypothesis that tissue factor and tissue-type plasminogen activator accelerate the activation of clotting and sequentially of fibrinolysis under conditions of low heparin concentrations in the pericardial cavity and that this local activation contributes highly to the systemic activation, affecting hemostasis during cardiopulmonary bypass. Topical use of heparin in the pericardial cavity therefore seems indicated to reduce blood activation during cardiopulmonary bypass.
N Tabuchi; J de Haan; P W Boonstra; W van Oeveren
Related Documents :
20951524 - Effects of therapeutic hypothermia on coagulopathy and microcirculation after cardiopul...
9341714 - Horseradish peroxidase as a histological indicator of mechanisms of porcine retinal vas...
8712454 - Phenylephrine increases cerebral blood flow during low-flow hypothermic cardiopulmonary...
2688284 - Cardiopulmonary resuscitation: current recommendations.
9177524 - Changes in liver function parameters after occlusion of gastrorenal shunts with balloon...
6774644 - Hyperventilation-induced cerebral hypoxia.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of thoracic and cardiovascular surgery     Volume:  106     ISSN:  0022-5223     ISO Abbreviation:  J. Thorac. Cardiovasc. Surg.     Publication Date:  1993 Nov 
Date Detail:
Created Date:  1993-12-08     Completed Date:  1993-12-08     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0376343     Medline TA:  J Thorac Cardiovasc Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  828-33     Citation Subset:  AIM; IM    
Thorax Centre, University Hospital Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Coagulation Factors / physiology
Cardiopulmonary Bypass*
Fibrinolysis / drug effects,  physiology*
Heparin / pharmacology
Middle Aged
Pericardium / physiology*
Platelet Activation / drug effects,  physiology*
Reg. No./Substance:
0/Blood Coagulation Factors; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cerebral vascular reactivity to carbon dioxide before and after cardiopulmonary bypass in children w...
Next Document:  Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experim...